6-month DMPA

Product Overview

Development Status: Active Development

Target: Female

Mode: Hormonal

Delivery Type: Injectable

Duration Type: Long-acting

Description: A single subcutaneous injection of medroxyprogesterone acetate injectable suspension, 150mg/mL, currently approved for intramuscular use every 3 months.

Updated date: June 02, 2017

Vertical Tabs

Status

Project Phase: Early Development

Project Stage: Phase I

Began discovery in: 2010

Status Details:
  • As of 2017, in active follow up of Phase I study.

Download Product Report